4-Acetoxy derivative(1) of L-703,717, a high-affinity (IC50=4.5nM) antagonist for the glycine site of NMDA receptors, was synthesized and its brain uptake was examined using a carbon-11 labeled analog ([11C]1).Initial radioactivity in the brain after intravenous injection of [11C]1 was a 2-fold that of [11C]L-703,717in mice.Rapid bioconversion of[11C]1 into [11C]L-703,717 was demonstrated by metabolite analyses of rat brain after [11C]1 injection. Ex vivo autoradiography of [11C]1 in rat brain showed the same cerebellar localization of radioactivity as [11C]L-703,717.These results indicate that 1 is a promising pharmacological tool as a prodrug of L-703,717 with improved BBB permeability
Abnormal activity of various N-methyl-d-aspartate receptor (NMDAR) subtypes has been implicated in a...
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) ori...
To evaluate in vivo brain penetration of alpha2C-adrenoceptor (alpha2C-AR) antagonists as a therapeu...
In previous studies, we have found that [11C]L-703,717,a positron-emitter labeled antagonist for the...
A positron-emitter (carbon-11) labeled antagonist for the glycine-binding site of NMDA receptors, [1...
GW196771 is a potent antagonist of the modulatory glycine site of the N-methyl-D-aspartate (NMDA) re...
Objective: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schi...
Selective inhibition of glycine transporter 1 (GlyT1) has emerged as a potential approach to allevia...
Selective inhibition of glycine transporter 1 (GlyT1) has emerged as a potential approach to allevia...
A quantitative autoradiographical technique has been employed to investigate the regional distributi...
A new derivative of 4,5,9,10-tetrahydro-1,4-ethanobenz[b]quinolizine (2) has been designed as a prod...
7-CHLOROKYNURENIC acid (7-Cl-KYNA) and 5,7-dichlorokynurenic acid (5,7-Cl2-KYNA) are of therapeutic ...
High-affinity iodine- and ethyl-C-5 substituted analogs of 4-hydroxy-3-(3-[11C]methoxyphenyl)-2(1H)-...
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) ori...
7-Chlorokynurenic acid 1 is a potent glycine-N-methyl-D-aspartate (NMDA) receptor antagunist, but it...
Abnormal activity of various N-methyl-d-aspartate receptor (NMDAR) subtypes has been implicated in a...
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) ori...
To evaluate in vivo brain penetration of alpha2C-adrenoceptor (alpha2C-AR) antagonists as a therapeu...
In previous studies, we have found that [11C]L-703,717,a positron-emitter labeled antagonist for the...
A positron-emitter (carbon-11) labeled antagonist for the glycine-binding site of NMDA receptors, [1...
GW196771 is a potent antagonist of the modulatory glycine site of the N-methyl-D-aspartate (NMDA) re...
Objective: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schi...
Selective inhibition of glycine transporter 1 (GlyT1) has emerged as a potential approach to allevia...
Selective inhibition of glycine transporter 1 (GlyT1) has emerged as a potential approach to allevia...
A quantitative autoradiographical technique has been employed to investigate the regional distributi...
A new derivative of 4,5,9,10-tetrahydro-1,4-ethanobenz[b]quinolizine (2) has been designed as a prod...
7-CHLOROKYNURENIC acid (7-Cl-KYNA) and 5,7-dichlorokynurenic acid (5,7-Cl2-KYNA) are of therapeutic ...
High-affinity iodine- and ethyl-C-5 substituted analogs of 4-hydroxy-3-(3-[11C]methoxyphenyl)-2(1H)-...
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) ori...
7-Chlorokynurenic acid 1 is a potent glycine-N-methyl-D-aspartate (NMDA) receptor antagunist, but it...
Abnormal activity of various N-methyl-d-aspartate receptor (NMDAR) subtypes has been implicated in a...
Objectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) ori...
To evaluate in vivo brain penetration of alpha2C-adrenoceptor (alpha2C-AR) antagonists as a therapeu...